Wells Fargo sees psychedelics market reaching $11B by 2035 https://www.investing.com/news/stoc...lics-market-reaching-11b-by-2035-93CH-4813495
Big Pharma wants to sell you psychedelic drugs https://spectator.com/article/big-pharma-wants-to-sell-you-psychedelic-drugs/?edition=us
Unlocking the Next Step in Compass’ Journey https://www.linkedin.com/pulse/unlocking-next-step-compass-journey-kabir-nath-d2zxc/
Three potential takeover targets in psychedelics https://www.pharmavoice.com/news/three-potential-takeover-targets-psychedelics-drug/826887/
Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights August 5, 2026 https://ir.compasspathways.com/News...-Results-and-Business-Highlights/default.aspx Data from two positive Phase 3 trials demonstrated rapid onset of effect and durable benefit through at least 6 months, further validating COMP360’s potential to establish a new standard of care in TRD COMP360 has a highly differentiated clinical profile and is expected to be a blockbuster opportunity, if approved Rolling NDA submission and initial review underway and final submission expected to be completed in Q4 Commercial launch expected in first half of 2027 COMP360 expected to fit seamlessly into current treatment infrastructure Late-stage PTSD trial underway Strong cash position of $433 million at the end of second quarter, providing cash well beyond launch and into 2028 Compass management will host a conference call on August 5 at 8:00 am ET
COMPASS Pathways investor presentation August 2026 https://s204.q4cdn.com/927483861/files/doc_presentation/2026/07/FINAL_CMPS_IR-Deck_AUG2026.pdf
Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin https://ir.compasspathways.com/News...estigational-Study-of-Psilocybin/default.aspx
Psychedelics on the cusp of market breakthrough as clinical, policy support grow https://www.biospace.com/drug-devel...-breakthrough-as-clinical-policy-support-grow
All eyes on psychedelic drugmakers as Definium, Compass near major catalysts https://www.biospace.com/drug-devel...kers-as-definium-compass-near-major-catalysts
Institute for Integrative Therapies Selected as Clinical Trial Site for COMPASS Pathways’ Psilocybin Treatment for PTSD https://www.einnews.com/pr_news/933...ompass-pathways-psilocybin-treatment-for-ptsd
Fireside chat at Canaccord Genuity's 46th Annual Growth Conference https://event.summitcast.com/view/W.../guest_book?session_id=JvK8yn9CBvACsVBtPgrxXU
VA Benefits: Trump Shares Update on Psychedelic Drug Treatment for Veterans https://www.newsweek.com/va-benefit...chedelic-drug-treatment-for-veterans-12344625
Radial Now Supports the Country's Largest Brain Medicine Clinical Network, Expanding Access to Breakthrough Treatments https://www.prnewswire.com/news-rel...atments-302855839.html?utm_source=chatgpt.com --- On August 20, 2026, Radial Health announced that it acquired the management-services organization supporting Mindful Health Solutions, creating what Radial describes as the largest U.S. “brain medicine” clinical network: 27 clinics, 100+ clinicians, and hundreds of thousands of patients, with explicit plans to offer psychedelic medicines in the near future. Mindful is already a major interventional-psychiatry operator and the second-largest U.S. administrator of Spravato, with established reimbursement relationships spanning Medicare, Tricare, VA-CCN, Aetna, Cigna, United and multiple Blue plans. Radial’s announcement specifically identifies COMP360 psilocybin among the emerging treatments the network is preparing to support.
Why pharmaceutical companies are interested in psychedelics https://www.marketplace.org/story/2026/08/20/why-big-pharma-wants-in-on-the-psychedelics-business
The White House’s MAHA Gatekeeper - https://www.theatlantic.com/politics/2026/07/heidi-overton-maha-rfk/688038/?utm_source=apple_news Almost tailor-made for $CMPS. FDA-regulated, conventional pharmaceutical development programs with randomized Phase 3 trials, defined doses, standardized manufacturing, safety databases, and eventual NDAs
VA’s Only Drug for Treatment-Resistant Depression Requires Up to 50 Visits a Year https://www.military.com/vas-only-d...nt-depression-requires-up-to-50-visits-a-year
States Should Start Planning Now For FDA Approval Of Psychedelics, Federal Report Says https://www.marijuanamoment.net/sta...approval-of-psychedelics-federal-report-says/ Report is here: https://www.govinfo.gov/content/pkg/FR-2026-07-14/pdf/2026-14158.pdf?utm_source=chatgpt.com Policymakers normally do not spend this much effort on state implementation, workforce preparation, rural clinics, VA deployment, reimbursement infrastructure, and rescheduling mechanics for something they think has no realistic chance of reaching patients.
Current Research, Regulatory, and Policy Considerations Regarding Psychedelics as Medicine (Substance Abuse and Mental Health Services Administration (SAMHSA) https://library.samhsa.gov/sites/de...ons-psychedelics-as-medicine-pep26-01-004.pdf This is a 2026 SAMHSA/HHS technical-assistance paper telling state and territorial mental-health leaders to start planning now for the fiscal, legal, workforce, Medicaid, and operational consequences of FDA-approved psychedelic medicines. It explicitly says states should develop oversight frameworks before these therapies become available.
Psychedelics Get Federal Attention @TheDalesReport https://www.youtube.com/live/10cdaXsPXcA?si=zh2kyqSlKRYOknXX&t=955 $DFTX$CMPS
